U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced plans for a nationwide advertising campaign encouraging Americans to adopt health wearables, such as heart rate and continuous glucose monitors. The initiative is part of the department’s broader “Making America Healthy Again” (MAHA) agenda.
Speaking before the House Energy and Commerce Committee’s Health Subcommittee, Kennedy emphasized the importance of personal health data. “My vision is that every American is wearing a wearable within four years,” he said. “It’s a way for people to take control of their health—seeing real-time impacts of food on glucose levels and heart rate.”
The announcement boosted shares of glucose-monitoring device makers. Dexcom (NASDAQ:DXCM) surged 10%, while Abbott gained 3.6% in afternoon trading.
Kennedy, a longtime advocate for preventive health and a critic of overreliance on pharmaceuticals, pointed to the cost-effectiveness of wearables compared to popular weight-loss drugs. “Ozempic costs $1,300 a month. If you can achieve similar results with an $80 wearable, that’s a better deal for Americans,” he noted. While he has criticized drugs like Novo Nordisk’s Ozempic, Kennedy supports their use for patients with morbid obesity or diabetes, when combined with exercise.
The campaign, which he described as one of the largest in HHS history, aims to shift the focus from reactive to proactive health management. Kennedy also hinted at exploring ways to subsidize wearables to make them more accessible.
J.P. Morgan analyst Robbie Marcus cautioned against assuming immediate changes in Medicare or insurance coverage for proactive monitoring, saying it’s too early to predict policy shifts.
The wearable tech market stands to benefit from this government push, as health monitoring tools become more mainstream in personal wellness strategies.


U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
UN General Assembly Demands Russia Return Ukrainian Children Amid Ongoing Conflict
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
U.S.-Russia Talks Leave Ukraine Peace Efforts Uncertain
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
Federal Judge Blocks Trump Administration’s Medicaid Funding Restrictions Targeting Planned Parenthood
Cuba Reaffirms Anti-Drug Cooperation as Tensions Rise in the Caribbean
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
U.S. Repatriation Flight Carrying 266 Venezuelan Migrants Lands in Caracas
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
U.S.–Russia Peace Talks Stall as Kremlin Rejects Key Proposals
Drones Spotted Near Zelenskiy’s Flight Path in Ireland Trigger Security Alert 



